Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Psilocybin in PTSD
NCT05562973Phase 1Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label trial of psilocybin in post-traumatic stress disorder (PTSD) (5 arms), sponsored by Johns Hopkins University. Primary endpoints: Mean Peak Post-Administration Blood Pressure, Mean Peak Post-Administration Heart Rate and 2 more. Planned start Jan 2025; status: withdrawn.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05562973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05562973.